

Setting up and Managing Investment Vehicles and Financial Instruments supporting Technology Transfer and Innovation

Our Experience

Workshop on Investment Vehicles and Financial Instruments supporting Technology Transfer and Innovation

focus on the Danube Region and the Western Balkan countries Belgrade, 1-2 March 2017 Venue: University of Belgrade and Science and Technology Park

Luigi Amati, Chairman and CEO

Our track record

INVESTMENTS: investing in companies

- Unique expertise in implementing public/private financial instruments
- 200+ companies, € 100+m invested, 1,3x FMV

EXPLOITATION: 3000+ entrepreneurs & scientists trained

- unique, proprietary formats
- investor readiness, exploitation plans, capacity building

POLICY: 700+ projects

- on innovation and entrepreneurship
- delivered worldwide to international, national, regional institutions



Business Case B-Shiver

Headquarters: Olbia (Italy)

Industry: Manufacturing **Investment**: € 3,000,000

Stage: Expansion

ZMV ownership: 43% Investment date: 2012 Valuation: not disclosed

To be noticed: innovative design






Short description: SNO Yachts is a company operating in the marine industry offering all kind of services for yachts ranging from 12 to 70 meters. Through the company B-Shiver, where the Ingenium Fund invested in 2012 to sustain the expansion stage, the group is producing and selling luxury yachts, under the brand Novamarine and Black-Shiver.

Use of proceeds: Thanks to Ingenium investment, the company has been able to reach high worth customers mainly in the Arabic Peninsula and to expand his producing facilities in Sardinia.



the batteries eries



Location: Warsaw, Poland

Industry: Energy

Investment Stage: Seed Investment date: 2017

ZMV investment: 3,0 Mln €

Status: unrealized



Business Case

Biogenera

Headquarters: Bologna (Italy)

Industry: Biotech

Investment: € 2,700,000

Stage: Seed

ZMV ownership: 42% **Investment date**: 2009

Valuation: € 50mln

To be noticed: The company

collected the interest of more than

40 business angels and MZV.





www.linkedin.com/company/biogenera-spa

Short description: Biogenera is a biotech company engaged in research and development of treatment for pediatric cancer. The company was founded in 2009 by two professors from Bologna University.

The monecule got recognition of Orphan Drug from EMA – the European Medicine Agency and it is now in this Phase I research.

Use of proceeds: The investment allowed the company to go through the pre-clinical and Phase I research.



Business Case Angiodroid

Headquarters: Bologna (Italy)

Industry: Medical Devices **Investment**: € 1,900,000


Stage: Start-up

ZMV ownership: 31%
Investment date: 2013
Valuation: not disclosed
To be noticed: patented

technology for the use of carbon

dioxide







Short description: Angiodroid developed and patented an innovative medical device for peripheral interventional angiography based on carbon dioxide controlled injection. The company is the first one substituting traditional iodinated contrast media in angiography procedures eliminating all related side effects associated with renal or diabetic vascular disease.

Use of proceeds: The company recently secured a first round of financing or around 1 mln Euro and will be looking for additional 2 mln in the following 12 months to push the commercialization of its devices in US, China and Brazil.



PORTFOLIO-OFIMETA INGENIUM DOG (SLOVENIA) OO (SLOVENIA)























BIAIseparationsations

BIA Separations is the leading developer and manufacturer of CIM® (Convective Interaction Media) monolithic chromatographic columns for production, purification, and analytics of large biomolecules.

BIA Separations has research, production and sales facility in Slovenia and sales offices in the US and China.



Location: Ljubljana/Ajdovščina

Industry: medtech

Investment Stage: Early


Expansion

Investment date: 2015 **ZMV investment**: 1.5 Mln €

Status: unrealized



How? Equity Co-Investment FI (Fund) for SMEs and start-up companies Off the shelf equity financial instrument





Why a commercially driven fund manager? How does an equity fund works in practice

- Successful Early stage Equity Funds focused on High Growth firm work with a portfolio of 10+ companies out of which majority will fail
- Reward for a fund manager is "carried interest" i.e. 20% of capital gains at the end of the fund life
- Private investors would like to see alignment of interest
- In "normal" funds, fund managers commit their own money into the fund to ensure alignment of interest with investors



Ensuring ring
Highgh
Quality
Deal Flow
Deal Flow











Building the co-investors base stors base

Italian Angels for Growth



Slovenian Angels





Lessons learnt

- A deal by deal co-investment approach at seed level is key to leverage at its best the contribution of the private sector
- Co-investment facility (not only the fund but also services) may include grants and advice to improve impact (investment readiness and scouting activities)
- Commercially driven fund manager is necessary to align interests,
 take the necessary risk and build the adequate portfolio
- The co-investment instrument attracts more private investors (Bas, VCs) and contributes to professionalization of the local community of business angels.



ITALY

Ms Francesca NATALI







SLOVENIA

Ms Nina MAZGAN

- Tehnološki park 19 1000 Ljubljana
- +386 3164 0789
- n.mazgan@meta-group.com

BELGIUM

Ms Andrea ARRECHEA ESSERY







POLAND

Mr Jacek BLONSKI

ul Bonifraterska 17 00-203 Warsaw

C +48 5348 0091 1

j.blonski@meta-group.com

www.meta-group.com

